Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2014-04-20
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-17 (study day 28.0); relationship: PROBABLE
mild
assessed
Mild ELECTROCARDIOGRAM ST SEGMENT DEPRESSION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-10-19 (study day 183.0); relationship: REMOTE
Data queries
No data queries.